Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Share:
Related JNJ
ETF Spotlight: Dividend Aristocrat Index
Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth
Franchise Fortunes Mark Shifts In Consensus For Marketed Products (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

DateFirmActionFromTo
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters